Exome CG

Nonacus introduces ExomeCG product to simplify molecular and cytogenomics data generation and interpretation

October 16, 2019

Birmingham, UK, 16 October 2019: Nonacus Ltd, a UK based precision medicine company and manufacturer of ultra-sensitive next-generation sequencing (NGS) products, has announced the launch of ExomeCG, a new product to simplify the generation and interpretation of molecular and cytogenomic data. The new product has been co-developed with digital health technology company, Congenica Ltd, which specialises in software solutions that enable accelerated interpretation of complex genomic data to improve disease diagnosis.

New QA / QC Production Scientist Role at Nonacus

June 18, 2018

We are excited to announce that Nonacus are recruiting! Following the successful launch of our Cell3TM DNA product range we are now growing the team and are seeking a highly motivated experienced Quality Assurance (QA) / Quality Control (QC) Production Scientist to join our team. The full job description and details on how to apply can […]

Why cfDNA has caused a revolution in genetic diagnostics

November 22, 2017

There’s been a revolution. It comes in the form of cell free DNA (cfDNA), which is changing patient pathways for the better across the globe. Due to its nature, cfDNA is considered as an excellent biomarker and source of genetic information. Cell free DNA is thought to originate predominantly from cells that undergo programmed cell […]

NIPD of fetal RhD takes step closer to EQA

November 22, 2017

Nonacus reviews latest accreditation efforts. Currently, the RhD genotyping landscape doesn’t feature a full EQA (European Quality Assurance) scheme but this latest report published in Blood Transfusion represents a big step forward towards an EQA. The authors have set themselves an objective to implement a regular EQA scheme through their working group. Chris Sale- CEO […]

Nonacus works with leading NHS laboratory on validating innovative product

November 22, 2017

New direct from plasma cfDNA test provides results in three hours. Since 2011 the NHS has been using cell free DNA (cfDNA) in fetal sex testing to identify pregnancies at high risk of sex-linked disorders. This test is done by extracting cfDNA from maternal plasma: a process that is slowing down results for patients. Nonacus […]

Nonacus launches Cell3™ Xtract kit to improve isolation of cell free DNA

September 20, 2017

Montpellier, Nonacus Ltd today announced the launch of a new DNA extraction kit designed to assist both researchers and clinicians translate the huge potential of circulating cell free DNA into improved patient care. Non-invasive screening of cell free DNA has already revolutionised the screening of conditions such as Down Syndrome in high risk pregnancies however […]

20-22 September 2017 – Nonacus to Attend CNAPS 2017

August 31, 2017

Nonacus is attending and sponsoring the 10th CNAPS International Symposium in Montpellier. Dr Michael Parks’ abstract has been accepted for an oral presentation: A direct from plasma approach to non-invasive prenatal fetal sex determination and RhesusD genotyping by quantitative PCR

27–30 May 2017 – Nonacus ESHG 2017 Abstract Accepted

March 26, 2017

Dr Michael Parks, previous recipient of the ESHG young investigator award, will be presenting a poster on our innovative Plasma Cell3TMDirect qPCR technology at the ESHG 2017 conference in Copenhagen:‘A direct from plasma approach to non-invasive prenatal fetal sex determination and RhesusD genotyping by quantitative PCR’(Control No. 2017-A-719-ESHG).

6-7th April – cfDNA 2017 Copenhagen

March 1, 2017

Nonacus is attending and sponsoring the 3rd International Meeting on Cell Free DNA conference in Copenhagen. Come and visit the team at booth H. Dr Michael Parks will be presenting our technology at the conference : A direct from plasma approach for non-invasive fetal RhesusD genotyping April 06, 2017, 16:10-16:45.

Next Page »